NEWS & PERSPECTIVES
Psychedelics News
Curated updates on microdosing, research, policy, and community.
The latest
Single-Dose Ayahuasca for Depressive and Anxiety Symptoms Associated With Cancer Diagnosis
This small, uncontrolled single-blind study (n=6 women with cancer) reported reductions in depressive and anxiety symptoms for up to three weeks after one ayahuasca session. No serious adverse effects were reported. T...
Single-Dose Ayahuasca for Depressive and Anxiety Symptoms Associated With Cancer Diagnosis
This small, uncontrolled single-blind study (n=6 women with cancer) reported reductions in depressive and anxiety symptoms for up to three weeks after one ayahuasca session. No serious adverse effects were reported. T...
‘Move Fast, with Precision’: Notes from ARPA-H’s Ibogaine Workshop
On Tuesday, the Advanced Research Projects Agency for Health (ARPA-H) held a day-long gathering related to its ibogaine funding opportunity, dubbed Accelerating Safe Clinical Evaluation of Novel Treatments: Ibogaine f...
Future Neuro Founders Program 2026
Our 3rd annual program starts Oct 9, for scientists who want to build startups.
Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target
TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of…
A single 1 mg/kg dose of psilocybin durably restored social novelty investigation in male SAPAP3 knockout mice and engaged prefrontal, hippocampal circuitry.
In a preclinical study in Molecular Psychiatry, psilocybin increased c-Fos activation in the medial prefrontal cortex and hippocampus across genotypes. In male SAPAP3 knockout mice, infralimbic cortex activation corre...
Add-on intravenous ketamine eliminates treatment lag period in severe non-treatment-resistant major depression: Rapid antidepressant and anti-suicidal effects – A randomized controlled trial
This small double-blind, placebo-controlled trial (n=40 adults with severe, non-treatment-resistant major depression) tested four add-on intravenous ketamine infusions (35mg/70kg) alongside usual antidepressant treatm...
Add-on intravenous ketamine eliminates treatment lag period in severe non-treatment-resistant major depression: Rapid antidepressant and anti-suicidal effects – A randomized controlled trial
This small double-blind, placebo-controlled trial (n=40 adults with severe, non-treatment-resistant major depression) tested four add-on intravenous ketamine infusions (35mg/70kg) alongside usual antidepressant treatm...
ARPA-H held a day-long Washington, D.C. workshop for potential applicants to its ASCENT-IBO ibogaine funding opportunity, with proposals due on 15 October.
The Advanced Research Projects Agency for Health hosted the Proposers’ Day to help prospective project teams connect and present ideas. ARPA-H expects proposals to cover clinical studies of ibogaine, ideally using a c...
What Lynn Watkins Actually Told the FDA about Chronic Pain and Psychedelics
Reuters attributed a quote about access and reimbursement to Lynn Watkins at Monday's FDA hearing on psychedelic drugs. She didn't say it. What she did say, in two minutes on the federal record, was about chronic pain...
Pα+ Psychedelic Bulletin #231: Compass Shares 52 Week Follow-Up, Training Grant Recipients; Xylo Enters the Clinic; RFK Jr. Hosts Hubbard
Compass Shares 52-Week Follow-Up and Five Training Grant Recipients Earlier this month, Compass Pathways shared topline data from Part C of its smaller, placebo-controlled Phase 3 trial, COMP005. As a reminder, COMP00...
Can psychedelic clinical trials be better? Researchers say yes
UC San Francisco researchers are weighing in on one of the biggest challenges in psychedelic science, arguing that clinical trials need more convincing placebo treatments to better measure the drugs' true effects.
What Makes a Good Psychedelic Therapist?
What Makes a Psychedelic Therapist Effective? As psychedelic-assisted therapy (PAT) moves toward regulatory approval, understanding what makes therapists effective becomes increasingly important. This article examines...
The Psychedelic Legacy Africa Still Isn’t Properly Credited For
Educator Darren Springer traces psychedelics back to where they actually began. [...] Read More...
Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026
LONDON & NEW YORK, September 16, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today…